Table 1. Baseline clinical characteristics and treatment of patients included in the plasma cfMBD-seq analysis.

Patient	Sex	Age range	Site	pT	pN	M	Tumor size (cm)	DOI (mm)	PNI	LVI	LN deposit (cm)	ENE	Previous treatment†
P1	Male	56–60	Mandible	4a	3b	0	5.3	30	Y	N	2.0	Y	Y
P2	Male	51–55	Mandible	4a	3b	0	4	28	N	N	2.5	Y	N
P3	Male	56–60	Tongue	4a	3b	0	6.5	35	Y	Y	1.9	Y	Y
P4	Female	65–70	Maxilla	1	X	0	0.3	1	N	N	N/A	N/A	N
P5	Male	76–80	Tongue	3	1	0	3.6	14	Y	N	0.9	N	N
P6	Female	41–45	Tongue	2	0	0	1.2	7	Y	Y	N/A	N/A	N
P7	Male	76–80	Tongue	4a	2a	0	5.2	41	Y	Y	1.7	Y	Y
P8	Female	76–80	Buccal Mucosa	1	1	0	2	2	N	N	0.6	N	N

^†P1 and P3 had undergone previous surgery and P7 had previously received cisplatin and radiation therapy.

^**pN – pathologic nodal classification; pT – pathologic tumor classification; M – Metastasis; PNI – Perineural invasion; LVI – Lymphovascular invasion; LN – Lymph Node; ENE – Extranodal extension